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Cytomegalovirus (CMV) reactivation after allogeneic hematopoietic cell transplant (allo-HCT) has been
associated with a reduced risk of relapse in patients with acute myeloid leukemia (AML). However, the in-
ﬂuence of the conditioning regimen on this protective effect of CMV reactivation after allo-HCT is relatively
unexplored. To address this, we evaluated the risk of relapse in 264 AML patients who received T cellereplete,
6/6 HLA matched sibling or 10/10 HLA matched unrelated donor transplantation at a single institution be-
tween 2006 and 2011. Of these 264 patients, 206 received myeloablative (MA) and 58 received reduced-
intensity conditioning (RIC) regimens. CMV reactivation was observed in 88 patients with MA conditioning
and 37 patients with RIC. At a median follow-up of 299 days, CMV reactivation was associated with signif-
icantly lower risk of relapse in patients who received MA conditioning both in univariate (P ¼ .01) and
multivariate analyses (hazard ratio, .5246; P ¼ .006); however, CMV reactivation did not signiﬁcantly affect
the risk of relapse in our RIC cohort. These results conﬁrm the protective effect of CMV reactivation on relapse
in AML patients after allo-HCT reported by previous studies but suggest this protective effect of CMV reac-
tivation on relapse is inﬂuenced by the conditioning regimen used with the transplant.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION et al. [7] found a modest protection against relapse in AML
Cytomegalovirus (CMV) is a double-stranded DNA b her-
pes virus that is generally of no major clinical signiﬁcance in
healthy immunocompetent hosts but is responsible for sig-
niﬁcant morbidity and mortality in immunocompromised
patients [1,2]. In patients with allogeneic hematopoietic cell
transplant (allo-HCT), the incidence of CMV disease has been
signiﬁcantly reduced because of early detection of CMV
reactivation and use of pre-emptive antiviral therapy. In spite
of this, CMV reactivation remains a signiﬁcant cause for
morbidity and mortality among allo-HCT patients [3-5].
Interestingly, in a recent study by Elmaagacli et al. [6], early
CMV pp65 antigenemia after allo-HCT was associated with
reduced risk of relapse in acute myeloid leukemia (AML)
patients. This study included a relatively homogeneous
population who underwent fully matched allo-HCT with
myeloablative (MA) conditioning. In a large cohort of
patients, using CMV pp65 antigenemia monitoring, Greenly to this study.
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13.10.003patients after allo-HCT, which included both MA and
reduced-intensity conditioning (RIC) patients, but the co-
horts were analyzed together with no subgroup analysis.
Currently, the inﬂuence of conditioning regimen on this
protective effect of CMV reactivation on the risk of relapse is
relatively unexplored. Quantitative CMV PCR (qPCR) is a
more sensitive assay compared with pp65 antigenemia for
CMV detection and has been shown to assist in early detec-
tion of CMV reactivation after allo-HCT, leading to prompt
pre-emptive treatment of CMV viremia [3,8,9]. Whether
implementing CMV qPCR instead of pp65 antigenemia assay
alters this association of reduced relapse risk with CMV
reactivation after allo-HCT in AML patients is also currently
not known. To address these questions, we retrospectively
analyzed 264 AML patients who received T cellereplete, 6/6
HLA matched sibling or 10/10 HLA matched unrelated donor
transplantation at a single institution between 2006
and 2011.METHODS
Study Population
The study included a total of 382 consecutive AML patients who un-
derwent allo-HCT at Washington University Medical Center at St. Louis
between January 2006 and December 2011. This study was approved by theTransplantation.
Table 2
Patient, Donor, and Transplant Characteristics by Intensity of Conditioning
Regimen
All
Patients
MA RIC P
Number of patients 264 125 139 d
Median patient age,
yr (range)
d 50 (17-68) 62 (21-73) <.0001
Patient sex (%) 1.0
Female 125 (47) 98 (48) 27 (47)
Male 139 (53) 108 (52) 31 (53)
Donor sex (%) .432
Female 88 (33) 66 (68) 22 (38)
Male 176 (67) 140 (32) 36 (62)
Donorepatient sex .755
Femaleemale 40 (15) 29 (14) 11 (19)
Other 224 (85) 177 (86) 47 (81)
Donorepatient CMV
status (%)
.0501
Negativeenegative 94 (36) 82 (40) 12 (21)
Negativeepositive 73 (28) 54 (27) 19 (34)
Positiveenegative 25 (9) 17 (8) 8 (14)
Positiveepositive 68 (26) 51 (25) 17 (30)
Unknown 4 (1)
Disease etiology .443
De novo 201 (76) 158 (77) 43 (74)
Secondary 42 (16) 30 (14) 12 (12)
Therapy related 21 (8) 18 (9) 3 (5)
Transplant type (%) .291
MRD 108 (41) 88 (43) 20 (34)
MUD 156 (59) 118 (57) 38 (66)
CMV reactivation .005
Yes 206 (78) 88 (43) 37 (64)
No 58 (22) 118 (57) 21 (36)
Disease classiﬁcation by
cytogenetics (%)
.154
Favorable 25 (9) 23 (11) 2 (3)
Intermediate 157 (60) 118 (58) 39 (67)
Poor 78 (30) 61 (30) 17 (29)
Unknown 4 (1)
Disease status at
transplant (%)
.012
CR1 135 (51) 100 (48) 35 (60)
CR2 43 (22) 43 (21) 15 (26)
Active disease 50 (19) 47 (23) 3 (5)
Other 21 (8) 16 (8) 5 (9)
aGVHD (%) .015
Grades 0-I 164 (63) 120 (58) 44 (76)
Grades II-IV 100 (37) 86 (42) 14 (24)
cGVHD (%) .273
No 172 (65) 130 (64) 42 (72)
Yes 89 (89) 73 (36) 16 (28)
Unknown 3 (1)
ATG regimen (%) <.0001
Yes 46 (17) 2 (1) 44 (76)
No 218 (83) 204 (99) 14 (24)
Stem cell source .429
Peripheral blood 240 (91) 185 (90) 55 (95)
Bone marrow 23 (9) 20 (10) 3 (5)
Missing information 1
Immune prophylaxis <.0001
MTX, MMF, tacrolimus 30 (11) 7 (3) 23 (40)
MTX, tacrolimus 215 (81) 181 (88) 34 (58)
Other* 19 (7) 18 (9) 1 (2)
MRD indicates matched related donor; MUD, matched unrelated donor; CR,
complete remission; MTX, methotrexate; MMF, mycophenolate mofetil.
* Other includes cyclosporine, MTX, sirolimus, and tacrolimus.
Table 1
Patient, Donor, and Transplant Characteristics
All
Patients
Patients
with CMV
Reactivation
Patients
without CMV
Reactivation
P
Number of patients 264 125 139 d
Median patient age,
yr (range)
d 56 (23-73) 51 (17-68) .005
Patient sex (%) .805
Female 125 (47) 58 (46) 67 (48)
Male 139 (53) 67 (54) 72 (52)
Donor sex (%) .696
Female 88 (33) 40 (32) 48 (35)
Male 158 (67) 85 (68) 91 (65)
Donorepatient sex .397
Femaleemale 40 (15) 15 (12) 25 (18)
Other 224 (85) 110 (88) 114 (82)
Donorepatient CMV
status (%)
<.0001
Negativeenegative 94 (36) 11 (9) 83 (60)
Negativeepositive 73 (28) 59 (48) 14 (10)
Positiveenegative 25 (9) 8 (7) 17 (12)
Positiveepositive 68 (26) 44 (36) 24 (17)
Unknown 4 (1)
Disease etiology .215
De novo 201 (76) 96 (77) 105 (75)
Secondary 42 (16) 16 (13) 26 (19)
Therapy related 21 (8) 13 (10) 8 (6)
Transplant type (%) .803
MRD 108 (41) 50 (40) 58 (42)
MUD 156 (59) 75 (60) 81 (58)
Conditioning regimen (%)
MA 206 (78) 88 (70) 118 (85) .005
RIC 58 (22) 37 (30) 21 (15)
Disease classiﬁcation
by cytogenetics (%)
.089
Favorable 25 (9) 17 (14) 8 (8)
Intermediate 157 (60) 70 (57) 87 (46)
Poor 78 (30) 35 (29) 43 (44)
Unknown 4 (1)
Disease status at
transplant (%)
.339
CR1 135 (51) 69 (55) 66 (48)
CR2 58 (22) 29 (23) 29 (21)
Active disease 50 (19) 29 (15) 31 (22)
Other 21 (8) 8 (6) 13 (9)
aGVHD (%) .446
Grades 0-I 164 (63) 81 (65) 83 (60)
Grades II-IV 100 (37) 44 (35) 56 (40)
cGVHD (%) .602
No 172 (65) 84 (68) 88 (64)
Yes 89 (34) 40 (32) 49 (36)
Unknown 3 (1)
ATG regimen (%) .009
Yes 46 (17) 30 (24) 16 (12)
No 218 (83) 95 (76) 123 (88)
Stem cell source .823
Peripheral blood 240 (91) 115 (92) 125 (91)
Bone marrow 23 (9) 10 (8) 13 (9)
Immune prophylaxis .023
MTX, MMF, tacrolimus 30 (11) 21 (17) 9 (6)
MTX, tacrolimus 215 (81) 97 (78) 118 (85)
Other* 19 (7) 7 (5) 12 (9)
MRD indicates matched related donor; MUD, matched unrelated donor; CR,
complete remission; MTX, methotrexate; MMF, mycophenolate mofetil.
* Other includes cyclosporine, MTX, sirolimus, and tacrolimus.
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Patient demographics and transplant characteristics were prospectively
entered into the Washington University School of Medicine, Blood and
Marrow transplant database. Of the 382 patients, 264 were selected for the
analysis based on following eligibility criteria: (1) 10/10 match at HLA loci A,
B, C, DRB1, and DQB1 by high-resolution genotyping in unrelated trans-
plantation [10] and by low resolution [11] in related donor transplantation;
(2) use of unmodiﬁed donor stem cells; (3) no use of prophylactic donor
lymphocyte infusion during the post-transplantation course among patientswithout leukemic relapse; (4) bone marrow biopsy done within 30 days
before transplantation to determine the disease status at the time of
transplantation; and (5) recipients of a second transplant were excluded
from the study group as prior transplantation.
The type of conditioning regimen patients received was classiﬁed ac-
cording to consensus deﬁnition of conditioning regimen intensity [12]. For
our study, RIC and non-MA regimens were grouped together under the RIC
cohort.
Table 4
Variables Inﬂuencing Risk of Relapse on Multivariate Analysis in the MA
Cohort
Figure 1. Cumulative incidence of relapse stratiﬁed by CMV reactivation in all patients, MA patients, and RIC patients.
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Monitoring for CMV reactivation was done with a real-time qPCR assay.
The theoretical lower limit of detection of the assay is 200 genome copies
per mL of blood (c/mL) and considered negative/undetectable below this
limit. The assay is accurate for quantitation>2000 c/mL, and any value>200
c/mL but <2000 c/mL was deﬁned as positive but not quantiﬁable. A CMV
viral load>2000 c/mLwas considered positivewith a quantiﬁable viral load.
CMV viral load >200 c/mL was considered as CMV reactivation, and this
value was used for analyzing its inﬂuence on relapse risk in this study.
Acute graft-versus-host disease (aGVHD) was diagnosed clinically based
on signs and symptoms and graded according to accepted criteria [13].
Chronic GVHD (cGVHD) was graded in accordance with National Institutes
of Health consensus criteria for diagnosis and grading [14].
Etiology of AML was classiﬁed into de novo AML without antecedent
diagnosis of bone marrow disorders such as myelodysplastic syndrome or
myeloproliferative disorder, secondary AML occurring from underlying bone
marrow disorders such as myelodysplastic syndrome or myeloproliferative
disorder, and therapy-related AML occurring as a result of prior exposure
to chemotherapy and/or radiation therapy per World Health Organization
classiﬁcation [15,16]. AML was classiﬁed into good, intermediate, and
poor prognostic groups based on cytogenetic and molecular abnormalities
[17-19]. Disease status at the time of transplant was classiﬁed as ﬁrst
complete remission, second complete remission, active disease, and “other”
based on the bone marrow biopsy done within 30 days before trans-
plantation [20,21] “Other” included patients who achieved remission for the
third time or beyond. Patients with persistent disease at the time of trans-
plantation were classiﬁed as active disease.
CMV Viremia Monitoring and Treatment
qPCR testing for CMV reactivation after allo-HCT was done at least twice
weekly for all inpatients and once weekly in the outpatient setting. CMV
viremia when detected and quantiﬁable was treated with intravenous
ganciclovir or oral valganciclovir for 14 days; if follow-up CMV qPCR showed
improvement in the viral load, then intravenous ganciclovir or oral val-
ganciclovir was continued on a maintenance dose until 2 consecutive qPCR
results were negative [22,23]. At that point, antiviral treatment was changed
back to either acyclovir or valaciclovir.Table 3
Variables Inﬂuencing Risk of Relapse on Multivariate Analysis
Parameter Parameter
Estimate
Standard
Error
P Hazard
Ratio
95% Hazard
Ratio
Conﬁdence
Limits
CMV (yes versus
no)
e.4427 .1965 .0242 .6423 .4370 .9440
cGVHD
(yes versus no)
e1.1237 .2243 <.0001 .3251 .2094 .5046
XRT regimen
(yes versus no)
.4407 .1948 .0237 1.5538 1.0606 2.2763
CMV indicates post-transplantation CMV reactivation (yes vs. no); XRT
regimen, use of radiation in conditioning regimen.Post-Transplantation Disease Monitoring
Patients underwent bone marrow biopsies after allo-HCT at 30 days,
100 days, and then every 6 months or earlier if there were any abnormal
ﬁndings noted on their peripheral blood suspicious for relapse. Relapse was
deﬁned per accepted criteria [16]. Morphologic relapse was the primary
outcome for patients transplanted in complete remission and progression of
disease for patients transplanted with active disease. Engraftment of the
donor cells was determined by Southern blot test for short tandem repeats
from peripheral blood mononuclear cells and/or bone marrow samples [24].
All patients were followed for CMV reactivation data until patients relapsed
or, for those without relapse, until death or the last clinic visit. Complete
donor engraftment was deﬁned by the presence of<5% of the recipient cells
obtained from bone marrow sample short tandem repeats. Recipient cell
percentage>5%was deﬁned asmixed chimerism. Extramedullary disease or
relapse was deﬁned by presence of blasts in tissue biopsy or by the presence
of morphologically or phenotypically positive blasts in the cerebrospinal
ﬂuid.Study Endpoints and Statistical Analyses
The primary study endpoint was cumulative incidence of relapse,
whereas secondary endpoints included overall survival (OS), relapse-free
survival (RFS), and nonrelapse mortality (NRM). Cumulative incidence of
relapse was compared between groups with and without CMV reactivation
for statistical signiﬁcance. Cumulative incidence of relapse was estimated by
treating death in remission as a competing risk event, and cumulative
incidence of NRMwas estimated by treating death in relapse as a competing
risk event. OS was deﬁned as the time from allo-HCT to death from any cause
or last follow-up. RFS was deﬁned as the time from allo-HCT to relapse or
death without relapse, whichever occurred ﬁrst.
Patient-, disease-, and treatment-related variables for the 2 study
groups were compared using the chi-square statistic or Fisher exact test forParameter Parameter
Estimate
Standard
Error
P Hazard
Ratio
95% Hazard
Ratio
Conﬁdence
Limits
CMV (yes
versus no)
e.6452 .2353 .0061 .5246 .3308 .8319
cGVHD (yes
versus no)
e1.0197 .2458 <.0001 .3607 .2228 .5840
XRT regimen
(yes versus no)
.5807 .2231 .0092 1.7873 1.1543 2.7674
ATG regimen
(yes versus no)
1.9601 .2753 <.0001 7.1002 4.1394 12.1787
CMV indicates post-transplantation CMV reactivation (yes vs. no); XRT
regimen, use of radiation in conditioning regimen; ATG regimen, use of ATG
in conditioning regimen.
Figure 2. RFS stratiﬁed by CMV reactivation in all patients, MA patients, and RIC patients.
S. Manjappa et al. / Biol Blood Marrow Transplant 20 (2014) 46e52 49categorical and the Kruskal-Wallis test for continuous variables. The cu-
mulative incidence plots were generated by SAS macro %CIF, and Gray’s test
was used to test equality of cumulative incidence function between the
2 study groups. Kaplan-Meier curves for OS were generated that provide
unadjusted survival estimates between study groups. Differences between
study groups were determined by log-rank tests. All statistical tests were
2-sided using a ¼ .05 level of signiﬁcance. SAS version 9.3 (SAS Institute,
Cary, NC) was used to perform all statistical analyses.
Univariate and multivariable proportional subdistribution hazards
models using the Fine and Gray approach [25] were considered to evaluate
the variables for relapse, treating death in remission as a competing event.
The variables included CMV reactivation status (yes versus no), cGVHD
(yes versus no), donorerecipient CMV status, use of radiation therapy in
conditioning regimen, use of antithymocyte globulin (ATG) in conditioning
regimen, and CMV reactivation within 100 days after transplantation (yes
versus no). A forward stepwise model selection approach was performed
to identify all signiﬁcant risk factors. Factors signiﬁcant at a 10% level were
kept in the ﬁnal model. CMV reactivation was forced into the multivariate
model. The cmprsk package in R (A Language and Environment for
Statistical Computing, Vienna, Austria) was used for this analysis (R
Foundation for Statistical Computing, Vienna, Austria). Moreover, the
Kolmogorov-Smirnov test and Cramer von Mises test in the timereg’s
comp. risk () function was used to test the time invariant effect for each
interested variables.RESULTS
Patient Characteristics
Based on CMV reactivation status, we divided our entire
patient cohort into 2 groups. Patient, disease, and transplantFigure 3. OS stratiﬁed by CMV reactivation in acharacteristics of these cohorts with and without CMV
reactivation are summarized in Table 1. A total of 125 pa-
tients had CMV reactivation, of which 100 had CMV reac-
tivation within the ﬁrst 100 days of transplantation. Median
time for CMV reactivation was 33 days (range, 3 to 666). A
total of 100 patients developed grades II to IV aGVHD: 44
(44%) in the CMV reactivation cohort and 56 (56%) in the
non-CMV reactivation cohort; this difference was not
statistically signiﬁcant (P ¼ .446). Similarly, a total of 89
patients developed cGVHD: 40 patients (45%) in the CMV
reactivation cohort and 49 (55%) in the non-CMV reac-
tivation cohort; this difference was also not statistically sig-
niﬁcant (P ¼ .602). One hundred eight patients underwent
matched related donor transplantation and 156 patients
underwent matched unrelated donor transplantation; this
difference in type of transplants (matched related donor
versus matched unrelated donor) between the cohorts with
and without CMV reactivation was not signiﬁcant (P ¼ .803).
Similarly, there was no signiﬁcant difference in distribution
by disease etiology, disease prognosis, or disease status at
transplantation. Distribution of gender was also similar
across both study groups.
There were few signiﬁcant differences between the
2 groups. Patients in the CMV reactivation group were older
and more likely to have a patientedonor combination ofll patients, MA patients, and RIC patients.
Figure 4. Cumulative incidence of NRM stratiﬁed by CMV reactivation in all patients, MA patients, and RIC patients.
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RIC allo-HCT and ATG as part of their conditioning regimens
were more likely to have CMV reactivation. Eighty-eight of
206 patients who underwent MA allo-HCT had CMV re-
activation, whereas 37 of 58 patients who underwent RIC
allo-HCT had CMV reactivation (P ¼ .005). Thirty of 46
patients with ATG in their conditioning regimens had CMV
reactivation compared with 95 of 218 patients without ATG
in their conditioning regimens (P ¼ .001). Patient chara-
cteristics of our RIC and MA cohorts are described in
Table 2.
CMV Reactivation and Risk of Relapse after Allogeneic
Transplantation
Using the highly sensitive qPCR method of CMV reac-
tivation monitoring, we evaluated the impact of CMV
reactivation on the risk of relapse in patients who under-
went allo-HCT. In our entire cohort of 264 patients, median
RFS was 287 (range, 1 to 2423). Among the entire cohort,113
patients (46%) relapsed at a median time of 140 days (range,
6 to 2041 days). Median RFS was 290 days (range, 23 to
2423) in patients with CMV reactivation and 285 days
(range, 1 to 2366) in patients without CMV reactivation. The
cumulative incidence of relapse among patients with CMV
reactivation was 31.4%, 37.1%, and 38.9% compared with
39%, 50%, and 59% for patients without CMV reactivation at
1 year, 3 years, and 6 years, respectively (Figure 1). In the
multivariable model, CMV reactivation was still signiﬁ-
cantly associated with reduced risk of relapse (hazard ratio,
.642; 95% conﬁdence interval, .44 to .94; P ¼ .024) (Table 3).
Thirty-seven patients relapsed within 100 days after their
transplantation, of which 27 patients relapsed before CMV
reactivation.
Subgroup analysis was performed to assess whether dif-
ferences in relapse existed with CMV reactivation in our MA
and RIC cohorts. In the MA cohort, 86 patients relapsed by
the end of the study. Median RFS was 333 days (range, 23 to
2423 days) in subjects with CMV reactivation compared with
283 days (range, 1 to 2093 days) without CMV reactivation.
Cumulative incidence of relapse was 28.6%, 33.7%, and 33.7%
at 1 year, 3 years, and 6 years, respectively, in patients with
CMV reactivation and 40%, 51.4%, and 55.4% at 1 year, 3 years,
and 6 years, respectively, in patients without CMV reac-
tivation (Figure 1). This decreased risk of relapse with CMV
reactivation in the MA cohort was signiﬁcant as anindependent factor in multivariate analysis (hazard ratio,
.525; 95% conﬁdence interval, .331 to .832; P ¼ .015) after
controlling for cGVHD, and use of ATG and radiation in the
conditioning regimen (Table 4). In the same analysis, cGVHD
was also associated with decreased risk of relapse (hazard
ratio, .364; 95% conﬁdence interval, .220 to .602; P <
.0001) in our MA cohort.
In contrast to these ﬁndings in our MA cohort, we did not
ﬁnd any signiﬁcant difference in the risk of relapsewith CMV
reactivation in our RIC cohort. In RIC patients, the median
RFS was 162 days (range, 26 to 2157 days) in patients with
CMV reactivation and 293 days (range, 16 to 2311 days) in
thosewithout CMV reactivation. The cumulative incidence of
relapse in these patients did not differ with CMV reactivation
(Figure 1).
Survival and Mortality with CMV Reactivation
As with cumulative incidence of relapse, we found
improved RFS with CMV reactivation in the entire and MA
cohorts but not in RIC patients (Figure 2). However, this
improved RFS did not translate into improved OS in any
patient cohort (Figure 3). A trend toward higher NRM with
CMV reactivationwas observed in the entire cohort (bothMA
and RIC patients) but did not reach statistical signiﬁcance in
any cohort (Figure 4).
DISCUSSION
Recently, several studies have addressed the impact of
CMV reactivation on risk of relapse after allo-HCT formyeloid
malignancies [6,26,27]. Consistent with the previous studies,
we show in our retrospective analysis that CMV reactivation
after allo-HCT leads to decreased relapse and improved RFS
in AML patients. In contrast to other studies, however, we
found this protective effect for relapse to be signiﬁcantly
inﬂuenced by the transplant conditioning regimen and to be
restricted to those AML patients undergoing MA allo-HCT.
Furthermore, our study used qPCR-based CMV monitoring
in contrast to pp65 CMV antigenemia testing used in previ-
ous studies. qPCR is more sensitive than pp65 anti-
genemiaebased assays used in previous reports [8,9]. In a
study by Schulenburg et al. [9], detection of CMV reactivation
by qPCR had a median lead time of 11 days before detection
by pp65 antigenemia and remained positive for a median of
16 days after testing negative for pp65 antigen. This leads to
early initiation and more prolonged antiviral treatment,
S. Manjappa et al. / Biol Blood Marrow Transplant 20 (2014) 46e52 51thereby potentially altering the impact of CMV reactivation
on relapse and survival beneﬁt. However, here we show
decreased relapse with CMV reactivation despite this po-
tential lead time for CMV treatment when using the highly
sensitive qPCR method of CMV monitoring in our allo-HCT
patients.
CMV-positive serostatus of the donor and recipients was
associated with reduced relapse rates in a pediatric popula-
tion who had undergone allo-HCT for acute leukemia [27]. In
a recent report by Elmagacli et al. [6], CMV reactivation in
AML patients after allo-HCT was associated with decreased
relapse and improved OS; however, this study only included
patients who received MA conditioning. Similarly, Green
et al. [7] observed a decreased risk of relapse with CMV
reactivation in a cohort of AML patients, including both MA
and RIC patients, that was more pronounced within the ﬁrst
100 days after transplantation and not statistically signiﬁcant
by 1 year. Both these studies used pp65 antigenemiaebased
monitoring for CMV reactivation.
Using both pp65 antigenemia and qPCR-based assays, Ito
et al. [28] found decreased relapse with CMV reactivation
after allo-HCT in CMV patients. Further, in our patients this
beneﬁcial effect of CMV reactivation on relapse was sus-
tained. Despite decreased risk of relapse and improved RFS,
we were unable to correlate improved OS with CMV reac-
tivation, which may be related to the increased NRM with
CMV reactivation because we saw a clear trend toward
increased NRM with CMV reactivation (although it did not
reach statistical signiﬁcance), and this increased NRM with
CMV reactivation was also reported by Green et al. [7]. Based
on these results, we hypothesize that decreased relapse risk
(and therefore improved RFS) and increased NRM compete
to inﬂuence OS in patients with CMV reactivation after allo-
HCT. This would explain the clear trend of decreased OS seen
in our RIC cohort where the lack of this protective effect on
relapse favors the balance toward poor OS (Figure 3).
The mechanism(s) behind decreased relapse with CMV
reactivation allo-HCT is currently not known. There has
been signiﬁcant interest in better understanding the impact
of natural killer (NK) cell alloreactivity on relapse, especially
in patients undergoing allo-HCT for myeloid malignancies
[29-31]. Foley et al. [32] found selective expansion of the
NKG2CþCD57þ NK cells with CMV reactivation, and these
cells have enhanced antileukemia responses in vitro. The
enhanced antileukemia responses by NKG2CþCD57þ NK
cells could potentially be responsible for enhanced NK
cellemediated “graft-versus-leukemia” (GVL) effect in vivo,
translating into less relapse in patients who reactivate CMV
after allo-HCT. Furthermore, CMV reactivation increases
leucocyte ﬁxation antigen-3 expression on blasts carrying
CMV, leading to enhanced NK cellemediated lysis of the
blasts [26,33]. The NK cellemediated GVL effect in general
seems to be restricted to patients with myeloid malig-
nancies and could be the reason why this CMV reac-
tivationerelated decreased relapse has been observed in
patients with myeloid malignancies [6,7,28-30]. Donor-
derived T cells could also be contributing to this “relapse
protective” effect from CMV reactivation. Leukemic blasts
could harbor CMV and, upon reactivation, activated donor-
derived T cells speciﬁc to CMV could therefore be directly
cytotoxic to these blasts expressing CMV antigens [26].
Thus, the GVL effect is pronounced in the scenario where
the recipient is seropositive than in any other combination,
and this has been demonstrated in our study as well as in
others [7]. The role of T cells in this enhanced GVL effect isunderscored by the failure to demonstrate decreased
relapse with CMV reactivation in a study where patients
underwent T celledepleted grafts with an alemtuzumab-
containing conditioning regimen [34].
In our RIC cohort, 44 of 58 patients received ATG as part of
their conditioning regimens. In vivo T cell depletion by ATG
in this cohort may result in mitigating the enhanced GVL
effect induced by CMV reactivation, therefore again under-
scoring the importance of graft-derived T cells in mediating
this effect. Further, host-derived memory T cells can persist
for up to 6 months in RIC patients and contribute toward
immunity against CMV [35,36]. Persistence of these host T
cells could contribute to clearing of CMV upon its reac-
tivation, thereby possibly preventing optimal donor T cell
and NK cell activation. Persistence of the host lymphocytes
early after allo-HCT in RIC patients could also compete for
cytokines with donor-derived T and NK cells and therefore
impair the enhanced GVL effect seen in the context of CMV
reactivation. The smaller RIC cohort could also be a factor for
not observing relapse beneﬁt. Further studies in a larger
cohort of patients with RIC regimens with and without ATG
would be prudent to better understand the role of the con-
ditioning regimen in this relapse beneﬁt from CMV
reactivation.
Reactivation of CMV after allo-HCT is traditionally
considered an adverse event needing aggressive therapy, and
most transplant centers monitor for CMV reactivation very
closely and institute aggressive pre-emptive therapy upon
evidence of CMV reactivation. Here we show that CMV
reactivation after allo-HCT, especially in MA conditioning
recipients, is associated with decreased risk of relapse and
improved RFS in AML patients. The mechanisms responsible
for this enhanced GVL effect with CMV reactivation need to
be further evaluated because a better understanding could
potentially lead to developing novel CMV antigenebased
vaccination strategies aimed at reducing relapse risk after
allo-HCT in the future.ACKNOWLEDGMENTS
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